Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 31;10(2):207.
doi: 10.3390/biom10020207.

Quercetin and Coumarin Inhibit Dipeptidyl Peptidase-IV and Exhibits Antioxidant Properties: In Silico, In Vitro, Ex Vivo

Affiliations

Quercetin and Coumarin Inhibit Dipeptidyl Peptidase-IV and Exhibits Antioxidant Properties: In Silico, In Vitro, Ex Vivo

Anand-Krishna Singh et al. Biomolecules. .

Abstract

Quercetin and coumarin, two naturally occurring phytochemicals of plant origin, are known to regulate hyperglycemia and oxidative stress. The present study was designed to evaluate the inhibitory activity of quercetin and coumarin on dipeptidyl peptidase-IV (DPP-IV) and their antioxidant potential. DPP-IV inhibition assays were performed, and evaluated IC50 values of diprotin A, quercetin, coumarin, and sitagliptin were found to be 0.653, 4.02, 54.83, and 5.49 nmol/mL, respectively. Furthermore, in silico studies such as the drug-likeliness and docking efficiency of quercetin and coumarin to the DPP-IV protein were performed; the ex vivo antiperoxidative potential of quercetin and coumarin were also evaluated. The results of the present study showed that the DPP-IV inhibitory potential of quercetin was slightly higher than that of sitagliptin. Virtual docking revealed the tight binding of quercetin with DPP-IV protein. Quercetin and coumarin reduced oxidative stress in vitro and ex vivo systems. We report for the first time that both compounds inhibited the DPP-IV along with antioxidant activity and thus may be use as function food ingredients in the prevention of diabetes.

Keywords: antiperoxidative; coumarin; diabetes; dipeptidyl peptidase-IV; hyperglycemia; quercetin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
The hydrogen bonding (A), hydrophobic binding (B), electrostatic binding (C), and secondary protein interaction (D) of diprotin-A and dipeptidyl peptidase-IV protein.
Figure 2
Figure 2
The hydrogen bonds (A), hydrophobic binding (B), electrostatic binding (C), and secondary protein interaction (D) of quercetin and dipeptidyl peptidase-IV protein.
Figure 3
Figure 3
The hydrogen bonds (A), hydrophobic binding (B), electrostatic binding (C), and secondary protein interaction (D) of coumarin and dipeptidyl peptidase-IV protein.
Figure 4
Figure 4
The hydrogen bonds (A), hydrophobic binding (B), electrostatic binding (C), and secondary protein interaction (D) of sitagliptin and dipeptidyl peptidase-IV protein.
Figure 5
Figure 5
β carotene bleaching inhibition (%) in quercetin and coumarin as compared to the control; ascorbic acid. Each vertical bar represents the mean ± S.E.M. (n = 3), *** p < 0.001, ** p < 0.01 and * p < 0.05 as compared to the respective control values. A. acid, ascorbic acid; Que, quercetin; Cou, coumarin.
Figure 6
Figure 6
Hepatic lipid peroxidation inhibition activities of quercetin and coumarin as compared to the control; ascorbic acid. Each vertical bar represents the mean ± S.E.M. (n = 3). *** p < 0.001, ** p < 0.01 and * p < 0.05 as compared to the respective control values. A. acid, ascorbic acid; Que, quercetin; Cou, coumarin.
Figure 7
Figure 7
Erythrocyte haemolysis inhibition efficacies of quercetin and coumarin as compared to the control; ascorbic acid. Each vertical bar represents the mean ± S.E.M. (n = 3). *** p < 0.001, ** p < 0.01 and * p < 0.05 as compared to the respective control values. A. acid, ascorbic acid; Que, quercetin; Cou, coumarin.

References

    1. Nyenwe E.A., Jerkins T.W., Umpierrez G.E., Kitabchi A.E. Management of type 2 diabetes: Evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60:1–23. doi: 10.1016/j.metabol.2010.09.010. - DOI - PMC - PubMed
    1. Chaudhury A., Duvoor C., Dendi R., Sena V., Kraleti S., Chada A., Ravilla R., Marco A., Shekhawat N.S., Montales M.T. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front. Endocrinol. (Lausanne) 2017;8:6. doi: 10.3389/fendo.2017.00006. - DOI - PMC - PubMed
    1. Holstein A., Hammer C., Hahn M., Kulamadayil N.-S.-A., Kovacs P. Severe sulfonylurea-induced hypoglycemia: A problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin. Drug Saf. 2010;9:675–681. doi: 10.1517/14740338.2010.492777. - DOI - PubMed
    1. Amiel S., Dixon T., Mann R., Jameson K. Hypoglycaemia in type 2 diabetes. Diabet. Med. 2008;25:245–254. doi: 10.1111/j.1464-5491.2007.02341.x. - DOI - PMC - PubMed
    1. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of hba1c. Diabetes Care. 2003;26:881–885. doi: 10.2337/diacare.26.3.881. - DOI - PubMed

Publication types

MeSH terms